Russian pharmaceutical company Petrovax on Thursday said 92.5 percent of Russian volunteers in trials of the Chinese Ad5-nCoV vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.
Ad5-nCoV was developed by Chinese company CanSino Biologics in alliance with the Chinese military's research arm.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3